Breast Imaging

Breast imaging plays an integral role in breast cancer screening and diagnosis. Screening mammography is performed in an asymptomatic woman in order to detect clinically occult breast carcinoma. Diagnostic mammography is performed to evaluate a questioned abnormality, detected either on clinical evaluation or on mammographic screening.

This section will review screening and diagnostic mammography, the role of additional mammographic views and other imaging modalities, the mammogram report using the terminology of the Breast Imaging Reporting and Data System (BI-RADS™) lexicon,  needle localization and image-guided percutaneous breast biopsy.

Mammography and breast magnetic resonance imaging (MRI) are currently the best available tools for detecting early breast cancer. Mammography may fail to detect some breast cancers. Importantly, mammography may miss some breast cancers in younger women. This is of concern because much of the BRCA1- and BRCA2-related breast cancer occurs before age 50.

In postmenopausal women, it is easier to detect a cancer by mammography, which appears as a white mass, or associated with white calcium spots, contrasted against a dark background. Before menopause, a woman’s breasts are made up of relatively more supporting tissue (which appears “dense” or white on a mammogram) and less fatty tissue (which appears “radiolucent” or dark).

Computer-assisted mammography reading and digital mammography are now being studied as ways to improve the accuracy of mammography interpretation. Annual breast MRI, an imaging technique that does not involve radiation exposure, is now rountinel recommended as a way to improve detection of early breast cancers when screening women at high genetic risk of breast cancer.

References

  1. American College of Radiology (ACR). Illustrated breast imaging reporting and data system (BI-RADSTM. 3nd ed. Reston [VA]: American College of Radiology, 1998.
  2. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds. Manual for Staging of Cancer, 4th ed. Philadelphia: JB Lippincott, 1992; 149-154.
  3. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24740 breast cancer cases. Cancer 1989; 63:181-187.
  4. Cody HS III, Laughlin EH, Trillo C et al. Have changing treatment patterns affected outcome for operable breast cancer? Ten year follow-up in 1288 patients, 1965-1978. Ann Surg 1991; 213:297-307.
  5. Silverstein MJ, Gierson ED, Waisman JR et al. Axillary lymph node dissection for T1a breast carcinoma: is it indicated? Cancer 1994; 73:664-667.
  6. Mustafa IA, Cole B, Wanebo HJ et al. The impact of histopathology on nodal metastases in minimal breast cancer. Arch Surg 1997; 132:384-391.
  7. Port ER, Tan LK, Borgen PI et al. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Ann Surg Onc 1998; 5:23-27.
  8. Kopans DB. Breast Imaging, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1998
  9. Kopans DB, ed. Health Effects of Exposure to Low Levels of Ionizing Radiation: BEIR V. Washington, DC: National Academy Press, 1990.
  10. Kopans DB. Breast Imaging, 2 1998; 105.
  11. Feig SA, Hendrick RE. Radiation risk from screening mammography of women aged 40-49 years. Monogr Natl Cancer Inst 1997; 22:119-124.
  12. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer 1977; 39:2772-2782.
  13. Shapiro S, Venet W, Strax P et al. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69:349-355.
  14. Shapiro S. Periodic screening for breast cancer: the HIP randomized controlled trial. Monogr Natl Cancer Inst 1997; 22:27-30.
  15. Baker LH. Breast cancer detection demonstration project: five-year summary report. CA 1982; 32:194-225.
  16. Seidman H, Gelb SK, Silverberg E et al. Survival experience in the breast cancer detection demonstration project. CA Cancer J Clin 1987; 37:258-290.
  17. Kopans DB, ed. The breast cancer screening controversy and the National Institutes of Health Consensus Development Conference on Breast Cancer Screening for Women Ages 40-49. Radiology 1999; 210: 4-9.
  18. Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. Monogr Natl Cancer Inst 1997; 22: 87-92.
  19. American College of Radiology (ACR). ACR Standard for the Performance of Screening Mammography. Reston [VA]: American College of Radiology; 1998: 37-41.
  20. Leitch AM, Dodd GD, Costanza M et al. American Cancer Society Guidelines for the Early Detection of Breast Cancer: Update 1997. CA Cancer J Clin 1997; 47:150-153.
  21. National Cancer Institute.
  22. Dershaw DD. Questions and Answers. AJR 1999; 172: 1136.
  23. Anderson BO, Senie RT, Vetto JT et al. Improved survival in young women with breast cancer. Ann Surg Oncol 1995; 2:407-415.
  24. Dershaw DD, Yahalom J, Petrek JA. Breast carcinoma in women previously treated for Hodgkin Disease: mammographic evaluation. Radiology 1992; 184:421-423.
  25. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. JAMA 1997; 277:997-1003.
  26. Burhenne LJW, Hislop TG, Burhenne HJ. The British Columbia Mammography Screening Program: Evaluation of the First 15 Months. AJR 1992; 158:45-49.
  27. Robertson CL. A private breast imaging practice: medical audit of 25,788 screening and 1,077 diagnostic examinations. Radiology 1993; 187:75-79.
  28. Sickles EA. Quality assurance: how to audit your own mammography practice. Rad Clin N America 1992; 30:265-275.
  29. Rosenberg RD, Lando JF, Hunt WC et al. The New Mexico Mammography Project. Screening mammography performance in Albuquerque, New Mexico, 1991 to 1993. Cancer 1996; 78:1731-1739.
  30. Brown ML, Houn F, Sickles EA et al. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR 1995; 165:173-177.
  31. Thurfjell E. Population-based mammography screening in clinical practice: results from the prevalence round in Uppsala County. Acta Radiol 1994; 35:487-491.
  32. Elmore JG, Barton MB, Moceri VM et al. Ten-year risk of false positive screening mammograms and clinical breast exams. N Engl J Med 1998; 338:1089-1096.
  33. Jackson VP. The current role of ultrasonography in breast imaging. Radiologic Clinics of North America 1995; 33:1161-1170.
  34. Stavros AT, Thickman D, Rapp CL et al. Solid breast nodules: Use of sonography to distinguish between benign and malignant lesions. Radiology 1995; 196:123-134.
  35. Morris EA, Schwartz LH, Dershaw DD et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 1997; 205:437-440.
  36. Harms SE, Flamig DP, Hesley KL et al. MR imaging of the breast with rotating delivery of excitation off resonance: Clinical experience with pathologic correlation. Radiology 1993; 187:493-501.
  37. Orel SG, Hochman MC, Schnall MD et al. High-resolution MR imaging of the breast: Clinical context. RadioGraphics 1996; 16:1385-1401.
  38. Orel SG, Schnall MD, Powell CM et al. Staging of suspected breast cancer: Effect of MR imaging and MR-guided biopsy. Radiology 1995; 196:115-122.
  39. Solomon B, Orel S, Reynolds C et al. Delayed development of enhancement in fat necrosis after breast conservation therapy: A potential pitfall of MR imaging of the breast. AJR 1998; 170:966-968.
  40. Gordon PB, Goldenberg SL. Malignant breast masses detected only by ultrasound: A retrospective review. Cancer 1995; 76:626-630.
  41. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US - diagnostic yield and tumor characteristics. Radiology 1998; 207:191-199.
  42. Slanetz PJ, Edmister WB, Weisskoff RM et al. Occult contralateral breast cancer detected by breast MR. Radiology 1998; 209(P):467.
  43. Liberman L, Abramson AF, Squires FB et al. The Breast Imaging Reporting and Data System: positive predictive value of mammographic features and final assessment categories. AJR 1998; 171:35-40.
  44. Sickles EA. Periodic mammographic follow-up of probably benign lesions: results in 3,184 consecutive cases. Radiology 1991; 179:463-468.
  45. Sickles EA. Nonpalpable, circumscribed, noncalcified solid breast masses: likelihood of malignancy based on lesion size and age of patient. Radiology 1994; 192:439-442.
  46. Varas X, Leborgne F, Leborgne JH. Nonpalpable, probably benign lesions: role of follow-up mammography. Radiology 1992; 184:409-414.
  47. Orel SG, Sullivan DC, Dambro TJ. BI-RADS™ categorization as a predictor of malignancy (abstr). Radiology 1997; 205 (P):447.
  48. Dershaw DD. Needle localization for breast biopsy. In: Dershaw DD, ed. Interventional Breast Procedures. New York: Churchill Livingstone, 1996:25-35.
  49. Helvie MA, Ikeda DM, Adler DD. Localization and needle aspiration of breast lesions: Complications in 370 cases. AJR 1991; 157:711-714.
  50. Whitman GJ, McCarthy KA, Hall DA et al. Retained hook-wire fragments in 12 patients: Mammography and management (abstr). Radiology 1993; 189 (P):326.
  51. Jackman RJ, Marzoni FA. Needle-localized breast biopsy: why do we fail? Radiology 1997; 204:677-684.
  52. Liberman L. Advantages and disadvantages of minimally invasive breast biopsy procedures. In: Parker SH, ed. Interventional Breast Procedures. In: Feig SA, ed. Seminars in Breast Disease 1998; 1: 84-94.
  53. Liberman L. Stereotaxic biopsy technique. In: Dershaw DD, ed. Interventional Breast Procedures. New York: Churchill Livingstone, 1996; 107-127.
  54. Parker SH, Jobe WE, Dennis MA et al. US-guided automated large-core biopsy. Radiology 1993; 187:507-511.
  55. Liberman L, Feng TL, Dershaw DD et al. US-guided core breast biopsy: use and cost-effectiveness. Radiology 1998; 208:717-723.
  56. Parker SH, Burbank F, Jackman RJ et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology 1994; 193:359-364.

Laura Liberman and Timothy L. Feng
Breast cancer detection demonstration project: five-year summary report. CA 2003

Provided by ArmMed Media